Arcutis Biotherapeutics (ARQT)
(Delayed Data from NSDQ)
$9.49 USD
-0.22 (-2.27%)
Updated Aug 12, 2024 04:00 PM ET
After-Market: $9.50 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
ARQT 9.49 -0.22(-2.27%)
Will ARQT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ARQT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ARQT
Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
ARQT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
Guardant Health (GH) Moves 6.9% Higher: Will This Strength Last?
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
Other News for ARQT
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024
Peeling Back The Layers: Exploring Arcutis Biotherapeutics Through Analyst Insights
Morgan Stanley Sticks to Its Buy Rating for Arcutis Biotherapeutics (ARQT)
Buy Rating Affirmed for Arcutis Biotherapeutics Amid Strong Zoryve Launch Prospects